Animal Blood Product Market Size, Share and Growth Outlook, 2026

Animal Blood Product Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Animal Blood Product Market size is forecast to increase from $5.26 Billion in 2026 to $9.31 Billion in 2034 at a CAGR of 7.4% between 2026 and 2034.

The Animal Blood Product market report provides detailed analysis and outlook of Animal Blood Product segments including By Product Type (Serum, Plasma and Plasma Fractions, Whole Blood Matrix, Red Blood Cells and Platelets, Blood Meal and Derivatives), By Application (Pharmaceuticals & Biologics Production, Diagnostics, Scientific Research & Development, Animal Feed and Nutrition Supplements), By Source Species (Bovine (Cattle), Porcine (Pigs), Equine (Horses), Companion Animals (Canine)), By Distribution Channel (Direct Sales, Distributors and Third-Party Suppliers, Online Sales Platforms), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Contract Research Institutes (CROs), Veterinary Hospitals, Commercial Animal Feed Manufacturers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Animal Blood Product Industry Overview

Biologics Manufacturing Driving Demand for Animal-Derived Blood Products

The animal blood product industry continues to play a critical role in the global biopharmaceutical and life sciences sectors, particularly through the supply of serum and plasma-derived materials used in research, vaccine production, and biologics manufacturing. The rapid expansion of cell therapy, gene therapy, and advanced biologic drug development programs is increasing demand for high-quality animal-derived blood products across regulated markets. Fetal Bovine Serum (FBS) remains one of the most widely utilized supplements in mammalian cell culture systems due to its ability to support cell growth, proliferation, and viability. As the number of biologics manufacturing facilities and clinical-stage regenerative medicine programs continues to expand, procurement requirements for validated and Good Manufacturing Practice (GMP)-compliant serum products are increasing significantly. This trend is reinforcing the strategic importance of reliable animal blood product supply chains within the biotechnology and pharmaceutical industries.

Advanced Processing Technologies Improving Product Quality

Manufacturers are increasingly adopting advanced plasma processing technologies to improve product consistency, protein integrity, and regulatory compliance. A major industry trend involves the transition from conventional plasma processing methods toward protein-specific fractionation techniques that enable the isolation and purification of targeted bioactive components. These technologies help maximize product functionality while meeting stringent quality requirements for research and industrial applications. Simultaneously, low-temperature spray-drying processes operating below 60°C are gaining traction across the industry. By minimizing thermal degradation, these processing methods preserve protein structure and biological activity, making them particularly valuable for applications requiring highly stable serum and plasma-derived products. Such innovations are enhancing product performance while supporting the growing needs of pharmaceutical manufacturing, biotechnology research, and cell culture applications.

Pathogen Safety and Regulatory Compliance Shaping Industry Standards

Quality assurance and biosafety considerations are becoming increasingly important within the animal blood product market as regulatory agencies impose stricter requirements on biologic raw materials. Manufacturers are placing greater emphasis on pathogen-inactivated plasma products to address concerns related to contamination risks and product safety. Enhanced pathogen reduction technologies are being integrated into plasma processing workflows to meet evolving regulatory mandates across major healthcare and biotechnology markets. The growing focus on traceability, validated production processes, and pathogen control reflects broader industry efforts to ensure the safety and reliability of animal-derived materials used in regulated therapeutic and research applications. These developments are driving continuous investment in advanced manufacturing technologies, quality management systems, and biosafety protocols throughout the animal blood product value chain.

Animal Blood Product Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Animal Blood Product market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Proliant Biologicals, Thermo Fisher Scientific Inc. (Gibco), Merck KGaA (Sigma-Aldrich), Bio-Techne Corporation, GeminiBio, Corning Incorporated, LAMPIRE Biological Laboratories, Inc., Bovogen Biologicals Pty Ltd, Pel-Freez Biologicals, Atlas Biologicals, Inc.. The Animal Blood Product market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Animal Blood Product industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Animal Blood Product Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Animal Blood Product companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Animal Blood Product markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Animal Blood Product Market Competitive Benchmarking and Company Analysis

Leading companies in Animal Blood Product industry include- Proliant Biologicals, Thermo Fisher Scientific Inc. (Gibco), Merck KGaA (Sigma-Aldrich), Bio-Techne Corporation, GeminiBio, Corning Incorporated, LAMPIRE Biological Laboratories, Inc., Bovogen Biologicals Pty Ltd, Pel-Freez Biologicals, Atlas Biologicals, Inc.. The Animal Blood Product market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Animal Blood Product Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Animal Blood Product market remains one of the strongest-performing segments in the country.
The US Animal Blood Product Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Animal Blood Product market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Animal Blood Product industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Animal Blood Product markets

Canada's strong Animal Blood Product sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Animal Blood Product market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Animal Blood Product Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Animal Blood Product market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Animal Blood Product population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Animal Blood Product industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Animal Blood Product market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Animal Blood Product sales through 2034

France Animal Blood Product companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Animal Blood Product Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Animal Blood Product distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Animal Blood Product Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Animal Blood Product market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Animal Blood Product industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Animal Blood Product industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Animal Blood Product Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Animal Blood Product market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Animal Blood Product market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Animal Blood Product Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Animal Blood Product Market Segmentation

By Product Type
Serum
Plasma and Plasma Fractions
Whole Blood Matrix
Red Blood Cells and Platelets
Blood Meal and Derivatives
By Application
Pharmaceuticals & Biologics Production
Diagnostics
Scientific Research & Development
Animal Feed and Nutrition Supplements
By Source Species
Bovine (Cattle)
Porcine (Pigs)
Equine (Horses)
Companion Animals (Canine)
By Distribution Channel
Direct Sales
Distributors and Third-Party Suppliers
Online Sales Platforms
By End-User
Pharmaceutical and Biotechnology Companies
Academic and Contract Research Institutes (CROs)
Veterinary Hospitals
Commercial Animal Feed Manufacturers

Top Companies in Animal Blood Product Industry

Proliant Biologicals
Thermo Fisher Scientific Inc. (Gibco)
Merck KGaA (Sigma-Aldrich)
Bio-Techne Corporation
GeminiBio
Corning Incorporated
LAMPIRE Biological Laboratories, Inc.
Bovogen Biologicals Pty Ltd
Pel-Freez Biologicals
Atlas Biologicals, Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025